ClinicalTrials.gg
WithdrawnNCT04282590Updated Mar 15, 2022

A Study to Investigate the Safety and Efficacy of TRK-750 for the Treatment of Patients With CIPN (Chopin Study)

A Phase 2 interventional study of TRK-750/Placebo and Placebo/TRK-750 in Chemotherapy-induced Peripheral Neuropathy, sponsored by Toray Industries, Inc. Withdrawn. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-03-15.

Sponsored by Toray Industries, Inc · Phase 2, Interventional, and Treatment

How we know

Why this study was withdrawn
due to COVID-19 pandemic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The primary objective of the study is:

  • to assess the safety and tolerability of multiple oral (twice daily [BID]) doses of TRK-750 in oxaliplatin-treated colorectal cancer patients with chemotherapy-induced peripheral neuropathy (CIPN).

The secondary objectives of the study are:

  • to assess the efficacy of multiple oral (BID) doses of TRK-750 in reducing neuropathic symptoms, improving quality of life (QoL), and clinician-reported outcomes in oxaliplatin-treated colorectal cancer patients with CIPN.
  • to study the relationship between plasma concentrations of TRK-750 and safety and efficacy variables in oxaliplatin-treated colorectal cancer patients with CIPN.

The exploratory objective of this study is:

  • to assess the efficacy of multiple oral (BID) doses of TRK-750 on pharmacodynamic (PD) biomarker(s) in blood, psychophysical, electrophysiological, and histological parameters of neuropathy in oxaliplatin-treated colorectal cancer patients with CIPN.
02

Conditions studied

  • Chemotherapy-induced Peripheral Neuropathy
03

In context

Lead sponsor

Toray Industries, Inc is the lead sponsor of 17 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patient between 18 and 80 years of age, inclusive.
  2. Oxaliplatin-containing chemotherapy treatment for colorectal cancer in the setting must have been completed ≥ 3 months, but not more than 3 years, prior to Screening.
  3. A diagnosis of CIPN based on the following criteria:

    1. onset of pain of any severity in hands and/or feet after exposure to oxaliplatin AND;
    2. presence of painful symptoms of any severity in a symmetrical stocking and glove distribution beginning in lower extremities, which may progress to the upper extremities (the latter may or may not be present at study entry) AND;
    3. painful symptoms are accompanied by non-painful symptoms (e.g., tingling or numbness) in a similar distribution.
  4. Neuropathy of ≥ Grade 2 using the general guideline of grading scales defined in (v5.0)
  5. Pain or neuropathic symptoms of CIPN for a duration of ≥ 3 months, for which the patient wants intervention.
  6. (BMI) between 18.0 and 32.0 kg/m2, inclusive.
  7. Females of will agree to use highly effective (Appendix 4) from the time of signing the ICF until 90 days after the Follow-up visit. Males who are sexually active with female partners of childbearing potential will agree to use a male condom with spermicide from Day 1 until 90 days after the Follow-up visit.
  8. Be either CIPN pain-treatment naïve or have important side effects or inadequate relief from their current CIPN pain medication (stable over last month).
  9. Has not used non-pharmacological therapy for the treatment of any pain condition (e.g., chiropractic therapies, alternative medicine therapies, or acupuncture) for at least 2 weeks prior to start of the baseline days (Days -14 to -1), and a willingness to refrain from using these therapies throughout the study. The use of physical activity or other short-acting, symptomatic non-pharmacological therapy is permitted provided the patient is willing to maintain the same regimen or usage pattern consistently throughout the study.
  10. Able to comprehend and willing to sign an Form (ICF) and to abide by the study restrictions.
  11. Patients have a of at least 12 months.
  12. An EORTC QLQ-CIPN20 score of ≥ 25 based on an average of 2 assessments during the Screening period and Day 1 prior to randomisation.
  13. At least one of the following:

    1. a mean value of pain intensity ≥ 4 on the 11-point NRS based on the average of once-daily assessments for 7 days, with no more than 2 missing records, between Days -7 and -1. Patients must score ≥ 4 on at least 4 out of 7 measurements between Days -7 and -1 OR;
    2. a mean value of intensity of tingling and numbness or uncomfortable neuropathic symptoms ≥ 4 on the 11-point NRS based on the average of once-daily assessments for 7 days, with no more than 2 missing records, between Days -7 and -1. Patients must score ≥ 4 on at least 4 out of 7 measurements between Days -7 and -1.

Exclusion criteria

Exclusion Criteria:

  1. Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol, ability to complete the study, and study assessments.
  2. Presence of skin conditions in the affected dermatome that, in the judgement of the Investigator, could interfere with evaluation of the neuropathic pain condition.
  3. Presence of non-CIPN pain that may interfere with study assessments and/or self-evaluation of peripheral neuropathic pain.
  4. Known history of significant , intolerance, or allergy.
  5. Peripheral neuropathy caused by tumour infiltration or compression of spinal nerves or surgical trauma.
  6. Active infection
  7. Unstable cardiac disease or myocardial infarction within 6 months prior to study entry.
  8. Patients with uncontrolled major psychiatric disorders, such as major depression or psychosis.
  9. History of pre-existing symptomatic neuropathy prior to chemotherapy, including neuropathy due to alcoholism, vitamin B deficiency, diabetes, hypothyroidism, (HIV), congenital neuropathy, and toxic neuropathy.
  10. Female patients who are pregnant (including a positive urine pregnancy test at Screening or on Day 1) or lactating.
  11. Inadequate haematological function, defined as \< 1.0 × 10\^9/L and count \< 50 × 10\^9/L with measured values of these in the clinical laboratory tests conducted at Screening. At Screening, haematology assessments may be repeated once.
  12. Inadequate renal function, defined as estimated (eGFR) ≤ 59 mL/min, i.e., (CrCl) as calculated using the Cockcroft-Gault equation with measured values of these in the clinical laboratory tests conducted at Screening:

    1. [1.23 × (140 - age) × (weight in kg)] ÷ (serum creatinine in μmol/L) - if male.
    2. [1.04 × (140 - age) × (weight in kg)] ÷ (serum creatinine in μmol/L) - if female.

    At Screening, clinical laboratory assessments may be repeated once.

  13. History of alcoholism or drug/chemical abuse within 1 year prior to Day 1.
  14. Positive test results for drugs of abuse at Screening (confirmed by repeat) or Day 1, unless consistent with use of prescription medication and approved by the Sponsor (or delegate). A repeated positive test result for cocaine, phencyclidine, methadone, or amphetamines, for nonmedical use, are unconditionally exclusionary.
  15. Positive test for surface antigen (HbsAg), antibody (HCV), or HIV antibody at Screening.
  16. Use of any medication in the absence of appropriate that, in the opinion of the Investigator, may influence the result of the study, or the patient's ability to participate in the study.
  17. Has received an product or has been treated with an investigational device within 90 days prior to first drug administration and will not start any other investigational product or device study within 90 days after last study drug administration.
  18. Likely to require chemotherapy during the study period or any other treatment that may interfere with compliance with the protocol, ability to complete the study, and study assessments.
  19. Plans to change current medications or any other intervention intended to treat or relieve CIPN signs or symptoms from Screening to end of study.
  20. Has previously received TRK-750.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Treatment Period 1: TRK-750, Treatment Period 2: placebo

    Drug: TRK-750/Placebo

  • Experimental
    Treatment Period 1: placebo, Treatment Period 2: TRK-750

    Drug: Placebo/TRK-750

Interventions

  • DrugTRK-750/Placebo

    Powder for oral solution

  • DrugPlacebo/TRK-750

    Powder for oral solution

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events as assessed by CTCAE v5.0

    Time frame: Up to Week 28

  2. Proportion of patients with clinically significant changes in vital signs: supine blood pressure (mmHg), supine pulse rate (beats/min), respiratory rate (breaths/min), and oral body temperature (°C or °F)

    Time frame: Up to Week 28

  3. Proportion of patients with clinically significant changes in electrocardiogram time intervals

    Time frame: Up to Week 24

  4. Proportion of patients with clinically significant changes in clinical laboratory tests

    Time frame: Up to Week 28

Secondary outcomes

  1. Absolute change and percentage change of Numerical Rating Scale (NRS) from baseline in neuropathic symptoms

    Pain and distressing neuropathic symptoms intensities will be assessed for neuropathic symptoms. * for pain intensity: weekly average of NRS daily (evening) assessments. * for distressing neuropathic symptoms such as tingling and numbness intensity: weekly average of NRS of daily (evening) assessments.

    Time frame: Week 12

  2. Proportion of patients with a reduction of at least 30% relative to baseline in neuropathic symptoms intensity on weekly average of NRS daily assessments

    Time frame: Week 12

  3. Change from baseline in EORTC QLQ-CIPN20 patient-reported outcome scale

    Time frame: Week 12

  4. Proportion of patients with 2 points or more improvement relative to baseline in EORTC QLQ-CIPN20 sensory subscale assessments

    Time frame: Week 12

  5. Change from baseline in EORTC QLQ-C30

    Time frame: Week 12

  6. Change from baseline in TNSc

    Time frame: Week 12

  7. Change from baseline in CTCAE (v5.0) neuropathy grade.

    Time frame: Week 12

  8. Plasma concentrations of TRK-750 (ng/mL)

    Time frame: Up to Week 28

Other outcomes

  1. Change from baseline in QST parameter: cold detection threshold (°C)

    The assessment will be study site dependent. For sites with the ability to perform the assessment, all patients will be evaluated.

    Time frame: Week 12

  2. Change from baseline in QST parameter: warm detection threshold (°C)

    The assessment will be study site dependent. For sites with the ability to perform the assessment, all patients will be evaluated.

    Time frame: Week 12

  3. Change from baseline in QST parameter: mechanical detection threshold (Von Frey filament detection [g])

    The assessment will be study site dependent. For sites with the ability to perform the assessment, all patients will be evaluated.

    Time frame: Week 12

  4. Change from baseline in QST parameter: vibration disappearance threshold (Hz)

    The assessment will be study site dependent. For sites with the ability to perform the assessment, all patients will be evaluated.

    Time frame: Week 12

  5. Change from baseline in QST parameter: cold pain threshold (°C)

    The assessment will be study site dependent. For sites with the ability to perform the assessment, all patients will be evaluated.

    Time frame: Week 12

  6. Change from baseline in QST parameter: heat pain threshold (°C)

    The assessment will be study site dependent. For sites with the ability to perform the assessment, all patients will be evaluated.

    Time frame: Week 12

  7. Change from baseline in QST parameter: mechanical pain threshold (mN)

    The assessment will be study site dependent. For sites with the ability to perform the assessment, all patients will be evaluated.

    Time frame: Week 12

  8. Change from baseline in QST parameter: pressure pain threshold (kPa)

    The assessment will be study site dependent. For sites with the ability to perform the assessment, all patients will be evaluated.

    Time frame: Week 12

  9. Change from baseline in electrophysiological amplitude in the sural, superficial radial, and tibial nerves: motor nerve (mV)

    The assessment will be study site dependent. For sites with the ability to perform the assessment, all patients will be evaluated.

    Time frame: Week 12

  10. Change from baseline in electrophysiological amplitude in the sural, superficial radial, and tibial nerves: sensory nerve (microV)

    The assessment will be study site dependent. For sites with the ability to perform the assessment, all patients will be evaluated.

    Time frame: Week 12

  11. Change from baseline in electrophysiological conduction velocity (m/sec) in the sural, superficial radial, and tibial nerves

    The assessment will be study site dependent. For sites with the ability to perform the assessment, all patients will be evaluated.

    Time frame: Week 12

  12. Restoring nerve fiber phenotype in punch skin biopsies (mm)

    The assessment will solely be at the discretion of the patient.

    Time frame: Week 12

  13. Change from baseline in Neurofilament Light Chain (pg/mL)

    Time frame: Week 12

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2020; primary completion for Dec 2021, 20 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2020
First posted
Feb 25, 2020
StartEst.
Apr 2020
Primary completionEst.
Dec 2021
CompletionEst.
Dec 2021
Last update
Mar 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04282590
Lead sponsor
Toray Industries, Inc
Responsible party
Sponsor
First posted
Feb 25, 2020
Start date
Apr 2020 (estimated)
Primary completion
Dec 2021 (estimated)
Completion
Dec 2021 (estimated)
Last update
Mar 15, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion